HomeCompareENBBF vs PFE

ENBBF vs PFE: Dividend Comparison 2026

ENBBF yields 6.10% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PFE wins by $28.8K in total portfolio value· pulled ahead in Year 9
10 years
ENBBF
ENBBF
● Live price
6.10%
Share price
$25.00
Annual div
$1.53
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.7K
Annual income
$0.63
Full ENBBF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — ENBBF vs PFE

📍 PFE pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodENBBFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ENBBF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ENBBF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ENBBF
Annual income on $10K today (after 15% tax)
$518.64/yr
After 10yr DRIP, annual income (after tax)
$0.54/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, PFE beats the other by $22,319.37/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ENBBF + PFE for your $10,000?

ENBBF: 50%PFE: 50%
100% PFE50/50100% ENBBF
Portfolio after 10yr
$35.2K
Annual income
$13,129.67/yr
Blended yield
37.35%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

ENBBF
Analyst Ratings
1
Hold
Consensus: Hold
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ENBBF buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricENBBFPFE
Forward yield6.10%6.13%
Annual dividend / share$1.53$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%13.2%
Portfolio after 10y$20.7K$49.6K
Annual income after 10y$0.63$26,258.71
Total dividends collected$621.00$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldHold

Year-by-year: ENBBF vs PFE ($10,000, DRIP)

YearENBBF PortfolioENBBF Income/yrPFE PortfolioPFE Income/yrGap
1$11,005$305.08$9,153$693.39+$1.9KENBBF
2$11,932$156.89$8,593$849.25+$3.3KENBBF
3$12,847$79.49$8,336$1,066.78+$4.5KENBBF
4$13,786$39.99$8,437$1,384.80+$5.3KENBBF
5$14,771$20.05$9,013$1,875.40+$5.8KENBBF
6$15,816$10.04$10,306$2,680.72+$5.5KENBBF
7$16,928$5.02$12,820$4,101.38+$4.1KENBBF
8$18,115$2.51$17,673$6,826.70+$442.00ENBBF
9← crossover$19,384$1.26$27,543$12,591.86$8.2KPFE
10$20,742$0.63$49,560$26,258.71$28.8KPFE

ENBBF vs PFE: Complete Analysis 2026

ENBBFStock

Enbridge Inc. operates as an energy infrastructure company. The company operates through five segments: Liquids Pipelines, Gas Transmission and Midstream, Gas Distribution and Storage, Renewable Power Generation, and Energy Services. The Liquids Pipelines segment operates pipelines and related terminals to transport various grades of crude oil and other liquid hydrocarbons in Canada and the United States. The Gas Transmission and Midstream segment invests in natural gas pipelines, and gathering and processing facilities in Canada and the United States. The Gas Distribution and Storage segment is involved in natural gas utility operations serving residential, commercial, and industrial customers in Ontario, as well as natural gas distribution and energy transportation activities in Quebec. The Renewable Power Generation segment operates power generating assets, such as wind, solar, geothermal, and waste heat recovery facilities; and transmission assets in North America and Europe. The Energy Services segment provides energy marketing services to refiners, producers, and other customers; and physical commodity marketing and logistical services in Canada and the United States. The company was formerly known as IPL Energy Inc. and changed its name to Enbridge Inc. in October 1998. Enbridge Inc. was founded in 1949 and is headquartered in Calgary, Canada.

Full ENBBF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this ENBBF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ENBBF vs SCHDENBBF vs JEPIENBBF vs OENBBF vs KOENBBF vs MAINENBBF vs JNJENBBF vs MRKENBBF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.